Director lunches and ‘excessive’ pay probed in biotech collapse
MELBOURNE: A collapsed biotechnology business ran into financial strife partly because of “excessive” ... read more
Imugene soars 30pc on gastric cancer trial
MELBOURNE: An ASX-listed immuno-oncology biotechnology company is providing fresh hope for gastric cancer ... read more
Barwon adds $45m in assets to healthcare fund
MELBOURNE: Barwon Investment Partners has swooped on four properties, worth $45 million in ... read more
